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a  b  s  t  r  a  c  t
The  aim  of  the study  was  to  determine  the  acute  effects  of positive  expiratory  pressure  (PEP) on  breathing
pattern,  operational  volumes  and  shortening  velocity  of respiratory  muscles  on  patients  with Parkinson’s
disease.  It was  evaluated  15 patients  and  healthy  controls,  by optoelectronic  plethysmography,  using
PEP  in  three  different  levels  (10, 15  and  20 cmH2O). Breathing  pattern  changed  in both  groups.  Parkinson
group  increased  tidal volume  in  all PEP  levels  (p  <  0.001),  but with  lower  values  compared  to control.  End-
inspiratory  chest  wall volume  increased  in  the  Parkinson  group  at  all PEP  levels  (p < 0.001),  end-expiratoryptoelectronic plethysmography
chest  wall  volume  show  a  slightly  increase  when  we  compared  QB to  all PEP  levels  in  Parkinson’s.  There
was  an  intergroup  difference  in  the index  of  shortening  velocity  of abdominal,  diaphragm  and  inspira-
tory  muscles  of the rib cage  at all PEP  levels  (p  < 0.01).  We  conclude  that  Parkinson’s  disease  promotes
important  alterations  in  different  breathing  pattern  components  and  PEP  has  signiﬁcant  effects  on  these
alterations.
©  2014  Elsevier  B.V.  All  rights  reserved.. Introduction
Parkinson’s is a chronic progressive neurodegenerative disor-
er characterized by a profound and selective loss of nigrostriatal
opaminergic neurons with the presence of eosinophilic, intracy-
oplasmic, proteinaceous inclusions (Lewy bodies) and dystrophic
ewy neuritis in the remaining neurons (Shobha et al., 2006;
homas and Beal, 2007).
Parkinson’s clinical alterations such as loss of movement
ontrol may  inﬂuence the respiratory system (Sande de Souza
t al., 2011; Brown et al., 1997). It has been reported that the
eduction of thoracic motion (Cardoso and Pereira, 2002; Pal et al.,
007), which results from posture alterations and osteoarticu-
ar degeneration, leads to an alteration in the spinal axis that
ffects breathing mechanics (Köseog˘lu et al., 1997). Phasic and
onic activity alterations of respiratory muscles may  also affect
he respiratory system. Several studies have observed restric-
ive breathing pattern characteristics in patients suffering from
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569-9048/© 2014 Elsevier B.V. All rights reserved.Parkinson’s with diminished lung function and reduced respiratory
muscles endurance and strength (De Pandis et al., 2002; Polatli
et al., 2001), as well as a decreased pulmonary compliance (Sabaté
et al., 1996; Brown, 1994).
Different types of respiratory therapies have been developed
recently, with the aim of decreasing or minimizing possible com-
plications caused by lung restriction. The application of Positive
expiratory Pressure (PEP) represents a reliable, safe and low-cost
intervention that allows increasing lung volumes and intrathoracic
pressure (Ricksten et al., 1986; Myers, 2007). Although positive
pressure therapy has been used in other respiratory and cardiac
diseases (Mortensen et al., 1991; Placidi et al., 2006), the possible
physiologic effects that different intensities of PEP may  cause in
chest volumes in Parkinson’s patients remains unknown.
PEP has been used to improve lung volume and consequently
oxygenation. More speciﬁcally, PEP improves collateral ventilation,
airways clearance, O2 distribution and increases functional residual
capacity. PEP also avoids small airways collapse, promotes greater
ventilation and increases expiratory time (Mestriner et al., 2009;
Fink, 2002).
The aim of the present study was  to determine the acute effects
of different levels of PEP on breathing pattern, operational volumes
of the chest wall and its different compartments (pulmonary rib
cage, abdominal rib cage and abdomen) and shortening velocity of
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. Methods
.1. Subjects
Subjects diagnosed with Parkinson’s disease and a control group
f healthy individuals, matched for age, gender and body mass
ndex, were recruited for the study. Parkinson’s subjects inclusion
riteria were patients diagnosed with stages II or III of Parkinson’s
isease according to the Hoehn and Yahr scale (Hoehn and Yahr,
967), subjects during “ON” condition, which is, under the effects
f Levodopa and not exhibiting cognitive disorders that could
ffect patients’ collaboration during the experimental procedures.
ndividuals showing pulmonary alterations, others than the ones
aused by Parkinson’s and mask discomfort as well as cognitive dis-
rders were excluded from the study. The study was  approved by
he Onofre Lopes University Hospital Research Ethics Committee
protocol no. 063/2011) and all patients signed informed written
onsent.
.2. Study design
The subjects from both groups were assessed on a single day,
eginning with anamnesis, physical examination consisting of
easuring vital signs [(blood pressure (BP), heart rate (HR) and
eripheral oxygen saturation (SatO2))], anthropometric character-
stics, spirometry and respiratory muscles strength. Successively,
ung volumes were measured before, during and after the experi-
ental protocol using Optoelectronic Plethysmography (OEP, see
elow).
.3. Spirometric assessment
The technical procedure, criteria of accessibility, reproducibility,
eference and interpretive values, standardization and equip-
ent followed the Brazilian Pneumology Society Guidelines (SBPT,
002). We  used a DATOSPIR 120 (SibelMed Barcelona, Spain) daily
alibrated, coupled to a microcomputer. Forced expiratory volume
n the ﬁrst second (FEV1), forced vital capacity (FVC), forced expi-
atory ﬂow between 25 and 75% (FEF25–75%), peak expiratory ﬂow
PEF) and the Tiffeneau index (FEV1/FVC) were considered. The
ighest spirometric values were considered for analysis and com-
ared with reference values validated for the Brazilian population
Pereira et al., 2007).
.4. Respiratory muscle strength
Respiratory muscle strength was assessed using a MICRO RPM
espiratory pressure meter (Micro Medical Ltd., Kent, England). The
ests were conducted with individuals in the sitting position imme-
iately after the pulmonary function test, with a resting period
etween tests. Before each test, the subjects were thoroughly
nstructed regarding procedures, and the results obtained were
ssessed in their absolute and relative values. For each assessment,
he maximum value obtained in at most ﬁve tests was considered,
rovided that this value was not greater than 5% between the three
ests. The values obtained were compared to a previously described
ormality curve (SBPT, 2002). The sniff nasal inspiratory pressure
SNIP) test was applied for 10 measures separated by a 30-second
esting period and performed from Functional Residual Capacity
FRC) (Heritier et al., 1994), using previously described equations
Araújo et al., 2012) to obtain reference values..5. Optoelectronic plethysmography (OEP)
Volume variations of total chest wall and its comportments,
amely pulmonary rib cage (RCp), abdominal rib cage (RCa) and& Neurobiology 198 (2014) 42–47 43
abdomen (AB) were measured by Optoelectronic plethysmogra-
phy (Aliverti et al., 2003). The motion of 89 reﬂective markers
positioned on the thoraco-abdominal surface [42 on the anterior
thoraco-abdominal wall, 37 on the back and 10 on the two lateral
sides (Gorini et al., 1999)] was  measured in three dimensions by
a set of TV cameras. Volumes were obtained by Gauss Theorem as
previously described (Cala et al., 1996; Aliverti and Pedotti, 2003).
2.6. Assessment of chest wall volumes using PEP
PEP was  applied by a PEP valve with adjustable load between 0
and 20 cmH2O (Vital Signs Inc., Totowa, NJ, United States), attached
to a face mask (Vital Signs, Atlanta, USA) adapted to ﬁt subjects
using headgear. Three different levels of PEP (10, 15 and 20 cmH2O)
were applied in random order to the subjects during chest wall
volumes measurement for 5 min. Resting quiet breathing (base-
line) values were recorded at the beginning of the protocol. For
each PEP level, chest wall volumes were measured during: (a) PEP
application and (b) recovery after PEP application. Recovery values,
recorded after the use of different levels of PEP, are shown as mean
value calculated among the three different moments (after PEP10,
PEP15 and PEP20) as they show no differences among them. Dur-
ing data acquisition, the subjects were in the sitting position with
hands on thighs and arms away from the trunk.
2.7. Analysis of lung volume variables
From OEP data, the following variables were considered for
further analysis: tidal volume of the chest wall (Vcw) and
its different compartments (Vrcp, Vrca, Vab); end-expiratory
and end-inspiratory total and compartmental chest wall vol-
umes, inspiratory (Ti) and expiratory (Te) time, total respiratory
cycle time (Ttot), respiratory rate (RR), total minute ventila-
tion (MinVent = Vcw*RR), mean inspiratory ﬂow (Vcw/Ti) and
mean expiratory ﬂow (Vt/Te). Vab/Ti, Vab/Te and Vrcp/Ti were
calculated as indexes of diaphragm, expiratory abdominal and
inspiratory rib cage muscle shortening velocities as previously
described (Aliverti et al., 2002, 2003).
Analyses were carried out disregarding the ﬁrst and last 30 s of
each condition (baseline, PEP, recovery), considering mean data of
the 30 most homogeneous seconds of the 240 remaining period.
2.8. Statistical analysis
Statistical procedures were performed using GraphPadPrism 5.0
software. Sample size was calculated based on standard devia-
tion of Vcw in a pilot study with 5 patients. A difference of 0.1 L,
with a power of 85% and p ≤ 0.05 indicated a sample size of 15
patients. The results are presented as mean and standard devia-
tion for parametric variables. Variable normality was  assessed with
the Shapiro–Wilk test. Unpaired t-test was  applied for intergroup
assessments, and two-way ANOVA with Bonferroni’s post hoc to
analyze the possible differences between variables studied during
the application of different PEP levels in both groups.
3. Results
3.1. Clinical aspectsThe Parkinson’s group exhibited signiﬁcantly lower spiromet-
ric and respiratory muscle strength values than the control group
(p < 0.01) (Table 1).
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Table  1
Anthropometric, pulmonary function and respiratory muscle strength characteris-
tics of both groups.
Parkinson’s group (n = 15) Control group (n = 15) p value
Age (years) 59.07 ± 9.34 58.80 ± 9.02 0.93
BMI  (kg/m2) 25.54 ± 3.03 26.20 ± 2.26 0.50
Gender (M/F) 12/03 12/03 1.0
Diagnosis (years) 4.07 ± 2.84 – –
FVC  (L) 3.09 ± 0.81 3.99 ± 0.93 <0.01
FVC  (% pred) 80.8 ± 16.71 96.87 ± 13.46 <0.01
FEV1 (L) 2.58 ± 0.65 3.17 ± 0.73 0.02
FEV1 (% pred) 85 ± 16.51 96.53 ± 12.12 0.03
FEV1/CVF 0.84 ± 0.06 0.80 ± 0.07 0.13
FEF25–75% 3.23 ± 0.89 3.62 ± 1.18 0.31
FEF25–75% (% pred) 112.1 ± 36.42 119.5 ± 32.69 0.56
PEF  (L/s) 5.09 ± 1.39 8.04 ± 1.66 <0.01
PEF  (% pred) 54.4 ± 15.82 83 ± 18.62 <0.01
MIP  (cmH2O) 82.13 ± 28.59 126.5 ± 46.66 <0.01
MIP  (% pred) 78.93 ± 23.33 120.8 ± 34.14 <0.01
MEP  (cmH2O) 101.5 ± 21.76 136.7 ± 33.33 <0.01
MEP  (% pred) 92.87 ± 17.65 124.7 ± 25.96 <0.01
SNIP (cmH2O) 72.80 ± 23.36 100.7 ± 27.87 <0.01
SNIP  (% pred) 70.13 ± 23.09 96.67 ± 25.82 <0.01
BMI: body mass index; FVC: forced vital capacity; FEV1: forced expiratory volume in

















b5  and 75%; PEF: peak expiratory ﬂow; IP max: maximum inspiratory pressure; EP
ax: maximum expiratory pressure; SNIP: sniff nasal inspiratory pressure % pred:
ercentage of predicted.
.2. Characterization of quiet breathing
We  found similar minute ventilation between the groups,
owever tidal volume was signiﬁcantly lower (p < 0.01) while respi-
atory rate was slightly higher in Parkinson’s compared to controls
uring quite breathing (Fig. 1). The lower tidal volume was due
ostly to a reduced tidal volume of the pulmonary rib cage.
.3. Effects of PEP on breathing pattern
Vcw was lower in Parkinson’s group during quiet breathing
nd at all levels of PEP compared to controls (p < 0.001). When we
ompared QB to PEP levels we found a signiﬁcant increase in Vcw
p < 0.001) at all PEP levels in both groups. Parkinson’s subjects did
ot show signiﬁcant differences between the three PEP levels while
ontrol group showed signiﬁcant differences between PEP10 and
EP15 (p < 0.05) and between PEP10 and PEP20 (p < 0.001). V  for
ig. 1. Minute ventilation in Parkinson’s subjects and control group during quite
reathing.& Neurobiology 198 (2014) 42–47
chest wall compartments was also signiﬁcantly lower when we
compared Parkinson’s to controls during all PEP levels (p < 0.05).
Intragroup analysis also showed signiﬁcant increase of V for all
compartments when we compared QB to PEP levels for both groups
(p < 0.05) with exception of Rca compartment for Parkinson’s that
showed signiﬁcant difference between QB and PEP 20 only (Fig. 2).
At recovery period, Vcw returned to quiet breathing values in both
groups (Fig. 2). We  found signiﬁcant difference in the compartmen-
tal distribution of Vcw percentage during quiet breathing and at
all levels of PEP (p < 0.0001) (Fig. 3).
In relation to breathing pattern time variables, Ttot, Ti and Te
were lower in the Parkinson’s group when compared to the con-
trol group during quiet breathing (p < 0.0001). Ttot and Ti were
lower in the Parkinson’s group (p < 0.0001) at all PEP levels. Te was
higher in the Parkinson’s group than in the control group only with
PEP10 (p < 0.0001). Ttot and Te increased in the Parkinson’s group
with PEP10 and PEP20 (p < 0.05). In relation to TI, signiﬁcant differ-
ences were observed only during PEP20 (p < 0.01). In the control
group Ttot increased at all PEP levels (p < 0.001), with differences
observed between PEP10 and PEP20 (p < 0.01), while Ti was  higher
at all PEP levels (p < 0.001). Te changed only during PEP15 and PEP20
(p < 0.001). In the recovery period Ttot, Ti and Te returned to quiet
breathing values.
When we compared QB with different levels of PEP we found
that RR is signiﬁcantly higher at QB in both groups (p < 0.005).
Intragroup analysis also showed that minute ventilation and mean
inspiratory ﬂow are signiﬁcantly higher during different PEP levels
compared to QB for both groups (p < 0.0001). Considering an inter-
group analysis we found that control group showed higher values
for minute ventilation and mean inspiratory ﬂow during all PEP lev-
els (p < 0.001) while mean expiratory ﬂow was signiﬁcantly higher
at PEP10 only (p < 0.05) (Fig. 4).
3.4. Effects of PEP on operational volumes
We  found an intergroup difference in end-expiratory chest wall
volume (EEVcw) variations at all PEP levels (p < 0.0001). EEVcw did
not increase in Parkinson’s group during different levels of PEP
(p > 0.05). The control group showed a decrease in EEVcw during
PEP15 and PEP20 (p < 0.05) with no differences between the levels.
A signiﬁcant difference was  observed in end-inspiratory chest wall
volume (EIVcw) variation when we compared quiet breathing to
all PEP levels in both groups (p < 0.01). EIVcw increased in Parkin-
son’s group at all PEP levels without differences between levels
(p < 0.001). In the control group EIVcw also increased for all PEP
levels (p < 0.001), and there was  a signiﬁcant difference between
PEP10 and PEP20 (p < 0.01). When we  assessed operational values
according to chest wall compartment we found that EEV for Rcp,
Rca and Ab were signiﬁcant different between the groups (p < 0.05).
EIV values for Rcp were signiﬁcant different between the groups
(p < 0.005). We  also found that EIV values were signiﬁcantly higher
for Rca and Ab compartments when we  compared QB to different
levels of PEP (p < 0.0001). Operational volumes returned to quiet
breathing values during the recovery in both groups (Fig. 5).
3.5. Effects of PEP on respiratory muscles shortening velocity
There was  an intergroup difference in the index of shorten-
ing velocity of abdominal, diaphragm and inspiratory muscles
of the rib cage when we  compared QB to PEP Levels (p < 0.01).
Vab/Te, used as an index of expiratory abdominal muscles short-
ening velocity, was  not inﬂuenced by PEP in Parkinson’s group
(p > 0.05), though the control group exhibited an increase at all
PEP levels (p < 0.01), without differences between them. Vab/Ti,
used as an index of diaphragm shortening velocity, was not inﬂu-
enced by PEP in Parkinson’s group (p > 0.05), while control group

















iig. 2. Effects of PEP on tidal volume of the chest wall and its compartments. QB: 
Intragroup difference comparing PEP10, p < 0.05. Intragroup difference comparing 
howed an increase at all PEP levels (p < 0.01), with no differences
etween levels. Vrcp/Ti, used as an index of inspiratory rib cage
uscles shortening velocity, also increased with PEP in control
roup (p < 0.001), with no differences between levels. During recov-
ry period the shortening velocity of diaphragm, abdominal and
nspiratory muscles of the rib cage returned to quiet breathing
alues.
. Discussion
In our study we were able to evaluate the effects of different
evels of PEP on different lung variables in Parkinson’s patients. Our
ata showed that Parkinson’s patients show less efﬁcient breathing
attern when compared to controls as it can be observed by the
ecreased tidal volume and increased respiratory rate showed
y these patients. Although the decreased Vt showed by these
atients we found that the use of different levels of PEP was able to
ncrease chest wall volume when compared to quite breathing. The
Fig. 3. Effects of PEP on compartmental distribution of tidal volume. QBbreathing. R: recovery. *Intragroup difference comparing quiet breathing, p < 0.05.
 p < 0.01. **Intergroup differences, p < 0.05.
distribution of Vcw among its compartments also varied between
the groups with the controls showing a more homogenous dis-
tribution compared to Parkinson’s. Another important ﬁnding is
that respiratory muscles strength was also lower in Parkinson’s
when compared to controls. Respiratory cycle time also differed
signiﬁcantly between the groups. Regarding operational volumes,
Parkinson’s patients exhibited lower values of EIV and higher
values of EEV compared to controls. Shortening velocity also
showed different pattern between the groups during PEP levels.
One possible explanation for the lower tidal volume showed in
Parkinson’s is mainly related to a rigid pulmonary rib cage com-
partment. Thus, the less effective effects of PEP in Parkinson’s are
mostly due to pulmonary rib cage restriction and inspiratory mus-
cle strength decrease. Moreover, we  were able to conﬁrm that
Parkinson’s patients show a mild restrictive pattern characteristic
when compared to healthy subjects. A previous study (Sabaté et al.,
1996) has related this pattern to posture alterations as limited trunk
ﬂexion, which changes the spinal axis, and thoracic mobility, with
: quiet breathing. R: recovery. **Intergroup differences, p < 0.01.
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Qig. 4. Effects of PEP on total respiratory rate, minute ventilation mean of inspirator
uiet  breathing, p < 0.05. **Intergroup differences, p < 0.05.
 thoracic motion range reduction which culminates in a decrease
f respiratory system complacency.
Sande de Souza et al. (2011) performed a study in which
hey evaluated 10 patients with Parkinson’s disease to 9 healthy
ubjects by electromyographic analysis and found that, low veloc-
ty is caused by low electromyographic activity and difﬁculty in
odulating explosive muscle power. Tremor was the signal that
ominated muscle activity, and it results from muscle contraction
ith irregular activation of motor units, which is considered an
ig. 5. Effects of PEP on operational volume of chest wall and its compartments in Parkin
B: quiet breathing. R: recovery. *Intragroup difference comparing quiet breathing, p < 0.05expiratory ﬂow. QB: quiet breathing. R: recovery. *Intragroup difference comparing
important factor for muscle weakness. According to our results, it
may  be hypothesized that the same pattern repeats itself in Parkin-
son’s respiratory muscles.
The use of PEP led to an increase of tidal volume in Parkinson’s
patients. Abdominal compartment accounted for more than half of
this volume in these patients. Based on the fact that we did not ﬁnd
any difference between the three levels of PEP we suggest that a
level of 10 cmH2O is able to reach important physiological changes
in this group. The different results observed in healthy controls may
son’s and controls.
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e related to rib cage restriction absence and preserved respiratory
uscle strength.
Furthermore, we may  attribute greater activity in the abdom-
nal compartment to restricted thoracic mobility in Parkinson’s
atients. Our ﬁnding differs from those reported by Parreira
t al., 2003, which compared the contribution of rib cage and
bdomen compartments to the tidal volume of 10 patients with
arkinson’s in the “ON” condition and 10 healthy individuals,
y respiratory inductance plethysmography. The study did not
nd signiﬁcant difference for abdominal compartment contribu-
ion between Parkinson’s patients and healthy subjects during
uiet breathing even with Parkinson’s showed higher absolute val-
es. Differences between the studies may  be related to the type
f equipment used in their investigation. Electrical inductance
lethysmography seems to be less accurate and is based in two
egrees of freedom to assess chest wall and its compartments
ovements. Thus, its capacity and accuracy is signiﬁcantly different
rom OEP.
Differences in respiratory cycle time may  be due to Parkinson’s
reathing pattern, which is characterized as superﬁcial with shorter
otal respiratory cycle time, inspiratory time and expiratory time
ompared to healthy individuals. Respiratory rate was  reduced in
arkinson’s patients at all PEP levels without differences between
hem. Thus, we suggest that the use of 10 cmH2O would be sufﬁ-
ient to reach physiological changes that would improve breathing
attern in Parkinson’s.
The end-expiratory volume in patients with Parkinson’s was
lightly higher after the use of PEP in contrast to healthy individuals,
ho exhibited negative variation and lung deﬂation with PEP15 and
EP20. We  believe that the lack of signiﬁcant increase of EEV after
he use of different levels of PEP in CF subjects is due to the small
ample size of our study. Regarding controls, which showed even
ecreased EEV values after the use of PEP in comparison to QB,
e may  speculate that PEP was not able to produce hyperinﬂation
n these subjects. PEP therapy caused modiﬁcations in Parkinson’s
atients, different from that observed in other pathologies, where
he use of PEP promotes pulmonary hyperinﬂation (Dellaca et al.,
001).
One hypothesis to explain differences between shortening
elocity pattern is related to the lower respiratory muscle strength
nd lesser motor unit activation (synchronization) in Parkinson’s
long with less rib cage mobility.
Based on our ﬁndings it is possible to conclude that Parkin-
on’s subjects exhibit important alterations in different breathing
attern components and that the use of PEP has signiﬁcant physi-
logical effects on breathing pattern and chest wall volumes even
ith 10 cmH2O.
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